These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30859549)

  • 21. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status.
    Ko YH; Cho EY; Kim JE; Lee SS; Huh JR; Chang HK; Yang WI; Kim CW; Kim SW; Ree HJ
    Histopathology; 2004 May; 44(5):480-9. PubMed ID: 15139996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
    Mehta-Shah N; Ito K; Bantilan K; Moskowitz AJ; Sauter C; Horwitz SM; Schöder H
    Blood Adv; 2019 Jan; 3(2):187-197. PubMed ID: 30670535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical characteristics and prognostic factors in 73 patients with peripheral T cell lymphoma].
    Huang XC; Li XL; Huang RX; Jin XS
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Feb; 33(2):151-5. PubMed ID: 18326910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
    Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N
    Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia.
    Kuzich JA; Hutchison AP; Lim KJC; Smallbone P; Denning K; Wright MP; Cull G; Leahy MF; Joske DJL; Radeski D; Purtill D
    Leuk Lymphoma; 2019 Dec; 60(14):3417-3425. PubMed ID: 31304820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of four prognostic scores in peripheral T-cell lymphoma.
    Gutiérrez-García G; García-Herrera A; Cardesa T; Martínez A; Villamor N; Ghita G; Martínez-Trillos A; Colomo L; Setoain X; Rodríguez S; Giné E; Campo E; López-Guillermo A
    Ann Oncol; 2011 Feb; 22(2):397-404. PubMed ID: 20631009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 30. [Peripheral T-cell lymphomas without primary skin involvement. An anatomicoclinical study of 29 consecutive cases].
    Salar A; Fernández de Sevilla A; Romagosa V; Domingo-Claros A; González-Barca E; Grañena A
    Med Clin (Barc); 1999 Feb; 112(7):255-6. PubMed ID: 10220752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
    Melchardt T; Troppan K; Weiss L; Hufnagl C; Neureiter D; Tränkenschuh W; Hopfinger G; Magnes T; Deutsch A; Neumeister P; Hackl H; Greil R; Pichler M; Egle A
    Br J Haematol; 2015 Jan; 168(2):239-45. PubMed ID: 25236324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nodal cytotoxic molecule (CM)-positive Epstein-Barr virus (EBV)-associated peripheral T cell lymphoma (PTCL): a clinicopathological study of 26 cases.
    Kato S; Takahashi E; Asano N; Tanaka T; Megahed N; Kinoshita T; Nakamura S
    Histopathology; 2012 Aug; 61(2):186-99. PubMed ID: 22690710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
    Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral T-cell lymphoma--not otherwise specified.
    Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
    Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
    Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study of prognostic related factors of elderly patients with T/NK cell lymphoma].
    Wang Y; Qian Y; Wu LL; Zhao BB; Xu PP; Zhao WL; Wang L
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):12-5. PubMed ID: 23597457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification.
    Kim K; Kim WS; Jung CW; Im YH; Kang WK; Lee MH; Park CH; Ko YH; Ree HJ; Park K
    Eur J Cancer; 2002 Jan; 38(1):75-81. PubMed ID: 11750843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
    Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
    Rodriguez-Pinilla SM; Domingo-Domenech E; Climent F; Sanchez J; Perez Seoane C; Lopez Jimenez J; Garcia-Cosio M; Caballero D; Blanco Muñez OJ; Carpio C; Castellvi J; Martinez Pozo A; Gonzalez Farre B; Bendaña A; Aliste C; Gonzalez AJ; Gonzalez de Villambrosia S; Piris MA; Gomez Codina J; Mayordomo-Aranda E; Navarro B; Bellas C; Rodriguez G; Borrero JJ; Ruiz-Zorrilla A; Grande M; Montoto C; Cordoba R
    Br J Haematol; 2021 Jan; 192(1):82-99. PubMed ID: 32426847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.
    Gritti G; Boschini C; Rossi A; Delaini F; Grassi A; Algarotti A; Micò C; Trezzi R; Gianatti A; Barbui AM; Rambaldi A
    PLoS One; 2015; 10(3):e0121822. PubMed ID: 25815886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.